The upcoming federal marijuana rescheduling hearing is already drawing controversy before it even begins.
According to reports, the Drug Enforcement Administration has restricted participation in its June 29 hearing on moving cannabis from Schedule I to Schedule III to a small group of selected stakeholders — and critics say the lineup is heavily tilted toward opponents of reform.
Advocacy groups, including NORML and other pro-reform organizations, argue that the exclusion of voices supporting rescheduling raises serious concerns about fairness and balance in a process that will help shape the future of federal cannabis policy.
The hearing is part of the broader effort to reconsider marijuana’s classification under the Controlled Substances Act, a process that could ultimately determine whether cannabis retains strict federal prohibition status or moves into a less restrictive category with recognized medical use.
While the DEA maintains authority over the administrative hearing process, reform advocates say limiting participation undermines the credibility of the review, especially given the national shift in public opinion and the expanding number of states with legal medical and adult-use cannabis programs.
Critics argue that excluding pro-reform voices creates a one-sided record at a moment when the stakes couldn’t be higher — not just for the cannabis industry, but for patients, consumers, and state-legal businesses operating in legal gray areas.
Supporters of rescheduling counter that the hearing process is procedural, not final decision-making, and that broader scientific and legal records will still guide the outcome.
Still, the optics are clear: as federal cannabis policy moves closer to potential change, the debate over who gets a seat at the table is becoming just as important as the decision itself.
Dabbin-Dad Newsroom
